Claims for Patent: 4,798,786

Summary for Patent: 4,798,786

Title:	Living cells encapsulated in crosslinked protein
Abstract:	Living cells are encapsulated by: (a) dispersing living cells in an aqueous solution of a capsule wall-forming protein; (b) forming aqueous droplets of the cell containing dispersion in an aqueous-immiscible, cell compatible continuous processing medium; and (c) crosslinking the protein with a crosslinking agent which is soluble in the continuous processing medium but substantially insoluble in the aqueous droplets. The resultant capsules containing living cells may be treated with a capsule wall degrading enzyme to enlarge pores of the capsules. The encapsulated cells may be used for administration of cells to an animal for growing the cells in the animal or for delivery to the animal of a substance produced by the cells. By the cells being encapsulated, the cells are not destroyed by the aminal immune system and immune response by the animal may be minimized.
Inventor(s):	Tice; Thomas R. (Birmingham, AL), Meyers; William E. (Helena, AL)
Assignee:	Stolle Research and Development Corporation (Cincinnati, OH)
Application Number:	06/375,710
Patent Claims:	1. A process for the encapsulation of living cells which comprises: (a) dispersing living cells in an aqueous solution of a capsule wall-forming protein; (b) forming aqueous droplets of said cell-containing dispersion in an aqueous-immiscible, cell compatible continuous processing medium; (c) crosslinking said protein with a crosslinking agent which is soluble in said continuous processing medium but substantially insoluble in said aqueous droplets thus forming crosslinked capsules, and adding to the formed crosslinked capsules a capsule wall degradation enzyme for a time sufficient to enlarge pore sizes in said walls to a predetermined average size. 2. The process of claim 1 wherein said aqueous solution also contains nutrients for said cells. 3. The process of claim 1 wherein said protein is selected from the group consisting of albumin, casein, collagen, gelatin, soy protein, gluten, and immunoglobulin. 4. The process of claim 1 wherein said solution also comprises an additional, enzyme-degradable material. 5. The process of claim 4 wherein said additional material is a polysaccharide, protein or nucleic acid. 6. The process of claim 1, wherein said cells are selected from the group consisting of animal, vegetable, microbiological, and artificially constructed cells. 7. The process of claim 4 wherein said cells are hybridoma cells. 8. The process of claim 4 wherein said cells are bacterial cells. 9. The process of claim 8 wherein said bacterial cells express a product coded by a non-bacterial gene which has been recombined into the DNA of said bacteria. 10. The process of claim 9 wherein said non-bacterial gene is a mammalian gene. 11. The process of claim 1 wherein said capsules have average diameters less than about 250 .mu.m. 12. The process of claim 1 wherein said processing medium is vegetable or mineral oil. 13. The process of claim 1 wherein said processing medium is selected from the group consisting of peanut oil, sesame oil and cottonseed oil. 14. The process of claim 1 wherein said crosslinking agent is at least a bifunctional agent capable of reacting with amino, hydroxy, carboxy or thiol groups of proteins. 15. The process of claim 14 wherein said crosslinking agent is a diacid halide. 16. The process of claim 15 wherein said diacid halide has the formula: wherein X is a halide, and n is an integer from 4 to 12. 17. The process of claim 1 which also comprises the step of washing the crosslinked capsules with an aqueous insoluble solvent. 18. The process of claim 1 wherein said aqueous solution of capsule wall forming protein also comprises a water soluble poragenic compound. 19. The process of claim 18 wherein said poragenic compound is present in said solution at from 1 mg/ml to 1 g/ml. 20. The process of claim 18 wherein said compound is selected from the group consisting of poly(vinyl alcohol), carboxymethyl cellulose, poly(vinyl pyrrolidone), starch or glycol. 21. The process of claim 18 wherein said compound is a polyglycol having a molecular weight from 100 to 10,000. 22. The process of claim 1 wherein said enzyme is a proteolytic enzyme. 23. The process of claim 1 wherein said enzyme is a polysaccharide degrading enzyme, a DNase, an RNase, keratinase, cellulase, amylase or collagenase. 24. The method of claim 1 wherein said wall has sufficient porosity to allow the passage therethrough of molecules having molecular weights in the range up to 500,000, or particles with a diameter up to about 3,000 .ANG.. 25. The method of claim 24 wherein said molecules are immunoglobulins. 26. The method of claim 25 wherein said immunoglobulins are monoclonal antibodies.

Details for Patent 4,798,786

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder	Powder	125696	01/31/2020		2039-03-29